<DOC>
	<DOCNO>NCT00039481</DOCNO>
	<brief_summary>Phase I trial study effectiveness oblimersen plus combination chemotherapy dexrazoxane treat child adolescent relapse refractory solid tumor . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Oblimersen may increase effectiveness doxorubicin cyclophosphamide make tumor cell sensitive drug . Chemoprotective drug dexrazoxane may protect normal cell side effect chemotherapy</brief_summary>
	<brief_title>Oblimersen Plus Combination Chemotherapy Dexrazoxane Treating Children Adolescents With Relapsed Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine dose-limiting toxic effect recommend phase II dose oblimersen combine cyclophosphamide , doxorubicin , dexrazoxane pediatric patient relapse refractory solid tumor . II . Determine pharmacokinetic behavior regimen patient . III . Determine , preliminarily , antitumor activity oblimersen patient . IV . Assess biologic activity oblimersen mononuclear cell tumor tissue , term bcl-2 relate protein expression , patient . OUTLINE : This 2-part , multicenter , dose-escalation study . Part A : Patients receive oblimersen IV continuously day 1-7 . Patients also receive dexrazoxane IV follow doxorubicin IV 15 minute follow cyclophosphamide IV 1 hour day 5 6 . Filgrastim ( G-CSF ) administer subcutaneously daily begin day 8 continue blood count recover . Treatment repeat every 21 day 18 course ( 1 year ) absence disease progression unacceptable toxicity . Patients stable respond disease whose shorten fraction fall 28 % echocardiogram whose total life-time cumulative anthracycline dose exceed 750 mg/m^2 may receive additional course oblimersen cyclophosphamide without doxorubicin dexrazoxane . Cohorts 3-6 patient receive escalate dos oblimersen maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Part B : Patients receive oblimersen MTD determine part A escalating dos dexrazoxane , doxorubicin , cyclophosphamide treatment schedule part A . Cohorts 3-6 patient receive escalate dos dexrazoxane , doxorubicin , cyclophosphamide maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Patients follow survival . PROJECTED ACCRUAL : A total 12-15 patient accrue study within 1-2 year .</detailed_description>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<criteria>Histologically confirm solid tumor original diagnosis fail standard therapy standard therapy exist Patients must disease know curative potential Patients must meet follow criterion bone marrow function : Status post stem cell transplantation ( SCT ) Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 ( transfusion independent ) Hemoglobin least 8.0 g/dL ( RBC transfusion allow ) No lymphoma No CNS tumor know metastatic disease brain spinal cord Performance status Karnofsky 50100 % ( age 11 21 ) Performance status Lansky 50100 % ( age 1 10 ) At least 8 week See Disease Characteristics Bilirubin great 1.5 time upper limit normal ( ULN ) ALT great 3 time ULN No significant hepatic dysfunction Creatinine clearance radioisotope glomerular filtration rate least 70 mL/min Creatinine , base age , follow : Age 1 5 : great 0.8 mg/dL Age 6 10 : great 1.0 mg/dL Age 11 15 : great 1.2 mg/dL Age 16 21 : great 1.5 mg/dL No significant renal dysfunction Shortening fraction least 28 % echocardiogram Ejection fraction least 45 % MUGA No significant pulmonary dysfunction Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious uncontrolled infection No endorgan dysfunction would preclude study entry No clinically significant systemic illness See Disease Characteristics Recovered prior immunotherapy At least 1 week since prior growth factor biologic agent At least 6 month since prior autologous SCT At least 6 month since prior allogeneic bone marrow transplantation recover evidence graftversushost disease No concurrent immunomodulating agent No concurrent prophylactic growth factor first course study No concurrent immunotherapy biologic therapy Recovered prior chemotherapy At least 2 week since prior myelosuppressive chemotherapy ( 6 week nitrosoureas ) No prior lifetime cumulative doxorubicin dose 450 mg/m^2 equivalent No concurrent chemotherapy Concurrent chronic steroid allow Recovered prior radiotherapy More 2 week since prior localize palliative radiotherapy ( small port ) More 6 month since prior substantial radiotherapy bone marrow ( craniospinal radiotherapy , total body irradiation , hemipelvic radiotherapy ) No concurrent radiotherapy Concurrent chronic medication ( e.g. , narcotic antiepileptic ) allow No concurrent investigational agent No concurrent cancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>